Finance Watch: Scorpion Closes $162m Series B, Bringing Recent Total To $270m
$1.67bn In New VC Deals Includes Nearly $1bn In Two Days
Executive Summary
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.
You may also be interested in...
Carisma Takes Its CAR-M Approach In Solid Tumors Public Via Sesen Merger
Merging with the shell of troubled cancer biotech Sesen, Carisma believes its chimeric antigen-receptor-macrophage (CAR-M) platform can bring the immunotherapy application to solid tumors.
LifeMine Gets Funding, Inks Discovery Alliance With GSK
Deal Snapshot: The fungi-derived medicine firm signed a three-candidate discovery and development deal with GlaxoSmithKline, which also contributed to its $175m series C round.
AstraZeneca Plans To Drug The Undruggable With Scorpion Partnership
The UK major will work with the US biotech to develop up to three precision medicines targeting cancer proteins previously thought undruggable via conventional methods.